Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
102.20    -1.00 (-0.97%)
Bid:
101.40
Ask:
102.20
Spread: 0.80 (0.789%)
Market Cap: £167.55m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Interim Management Statement

10 Nov 2011 07:00

RNS Number : 8260R
Yule Catto & Co PLC
10 November 2011
Β 

ο»Ώ

10 November 2011

Β 

Yule Catto & Co plc (the "Group")Β 

Β 

Interim Management Statement

Β 

Yule Catto & Co plc (the "Group"), the international producer of speciality chemicals, today issues its interim management statement for the period 1 July to 9 November 2011.

Β 

The Group has performed well, in what has been a period of considerable economic uncertainty, and earnings for the third quarter were slightly ahead of the Board's expectations as at the date of the interim results.

Β 

The Polymers business saw generally softer demand across all regions compared to the first half of the year, as the customer destocking which started in July and August at the time of the Group's interim statement continued through the period resulting in a modest reduction in volumes. Monomer prices fell back through the period following the steep increases experienced through 2010 and the first half of 2011, with substantial falls in September and October. The benefit of weakening input prices and product price management ensured that third quarter pro-forma profitability continued to be comfortably ahead of prior year.

Β 

The delivery of synergies from the PolymerLatex acquisition continues to progress well and to plan. After six months of ownership, synergies had reached an annualised run rate of Β£8M at the end of the third quarter. The Board remains highly confident of achieving the planned annual synergies from the acquisition of at least Β£20M in the second 12 months post acquisition.

Β 

Pharma division profits year to date were similar to prior year.

Β 

Net debt reduced to Β£226M at the end of September from Β£240M at the end of June.

Β 

On 17 October, the Group announced the acquisition of Quality Polymer, a Malaysian aqueous polymer producer, expanding the Group's South East Asian production and sales of acrylic and vinylic polymer dispersions and adding a facility located close to Yule Catto's existing plant in Pasir Gudang.

Β 

The Board believes the current softer demand is attributable to destocking, along with some end market weakness. Based on current performance, the Board expects the Group will deliver full year earnings at least in line with current market expectations.

Β 

- Ends -

Β 

ENQUIRIES:

Β 

Yule Catto & Co plc

Tel: 01279 442791

Adrian Whitfield, Chief Executive

David Blackwood, Group Finance Director

MHP Communications

Tel: 020 3128 8100

Andrew Jaques

John Olsen

Ian Payne

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
IMSLLFLTLALAIIL
Date   Source Headline
1st Jun 20262:42 pmRNSHolding(s) in Company
29th May 20263:57 pmRNSTotal Voting Rights
22nd May 20265:21 pmRNSNotice of AGM
8th May 20264:33 pmRNSAdmission to Trading
7th May 20261:51 pmRNSApplication for Admission to Trading
5th May 20264:25 pmRNSHolding(s) in Company
30th Apr 20264:40 pmRNSAnnual Financial Report
30th Apr 20263:17 pmRNSDirector/PDMR Shareholding
30th Apr 202611:25 amRNSDirector/PDMR Shareholding
30th Apr 20267:01 amRNSChange of Chief Financial Officer
30th Apr 20267:00 amRNSFinal Results
19th Mar 20267:00 amRNSTrading and refinancing update
11th Feb 20261:46 pmRNSStatement re potential refinancing
29th Jan 20267:00 amRNSTrading Statement - Winter 2026
27th Jan 20264:51 pmRNSHolding(s) in Company
26th Jan 20264:23 pmRNSHolding(s) in Company
18th Dec 20257:00 amRNSReceivables purchasing arrangement
12th Dec 20259:30 amRNSDirectorate change
12th Nov 20257:00 amRNSDirector/PDMR Shareholding
5th Nov 20251:28 pmRNSHolding(s) in Company
23rd Oct 20257:00 amRNSTrading statement - Autumn 2025
14th Oct 20257:00 amRNSAppointment of joint corporate broker
4th Sep 20255:17 pmRNSHolding(s) in Company
11th Aug 20258:00 amRNSDirector/PDMR Shareholding
6th Aug 20259:45 amRNSDirector/PDMR Shareholding
5th Aug 202511:57 amRNSDirector/PDMR Shareholding
5th Aug 202511:00 amRNSDirectorate Change
5th Aug 20257:00 amRNSInterim results
4th Jul 20257:01 amRNSDirector/PDMR Shareholding
1st Jul 20257:00 amRNSCovenant update
30th Jun 20257:00 amRNSDirectorate Changes
27th Jun 20254:21 pmRNSHolding(s) in Company
2nd Jun 20257:00 amRNSDivestment of William Blythe completed
6th May 20257:00 amRNSDivestment of William Blythe
1st May 20254:18 pmRNSResults of AGM
1st May 20257:00 amRNSTrading Statement - Spring 2025
15th Apr 20253:00 pmRNSHolding(s) in Company
28th Mar 20257:30 amRNSDirector/PDMR Shareholding
27th Mar 20257:30 amRNSDirector/PDMR Shareholding
25th Mar 20254:23 pmRNSAnnual Report and Notice of AGM
25th Mar 202511:43 amRNSDirector/PDMR Shareholding
25th Mar 202511:41 amRNSDirector/PDMR Shareholding
24th Mar 20257:30 amRNSHolding(s) in Company
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
11th Mar 20257:00 amRNSFinal Results
6th Mar 20258:32 amRNSDirector Declaration
13th Feb 20257:00 amRNSHolding(s) in Company
28th Jan 202510:30 amRNSDirector/PDMR Shareholding
28th Jan 20257:00 amRNSWinter trading statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.